Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05969054
Status:
RECRUITING
Last Update Posted:
2023-08-04
First Post:
2023-07-12
Brief Title:
Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimers Disease Patients With Epilepsy
Sponsor:
Xiangya Hospital of Central South University
Organization:
Xiangya Hospital of Central South University
Study Overview
Official Title:
A Clinical Study Exploring Lacosamide and Levetiracetam in Improving Cognitive in Patients With Alzheimers Disease and Epilepsy
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participants will perform Mini-Mental State Examination MMSE Montreal Cognitive Assessment MoCA Clinical Dementia Rating CDR Alzheimers disease assessment scale-cognitive section ADAS-Cog Hamilton Anxiety Scale HAMA and Hamilton Depression Rating Scale HAMD evaluation The patients will be randomly divided into two groups treated with lacosamide and levetiracetam respectively and maintained for 6 months
Researchers will compare the lacosamide group with the levetiracetam group to see if the improvement of cognitive function in the two groups
Researchers will compare the lacosamide group with the levetiracetam group to see if the improvement of cognitive function in the two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None